Quidel Corporation (QDEL) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Total Cash From Operating Activities Chart for Quidel Corporation
Quidel Corporation (QDEL) operating cash flow for FY2025 was USD 105.2M, a 26.7% change from FY2024. Quidel Corporation's operating cash flow moved from USD -3.3M in 1991 to USD 105.2M in 2025 over 34 years. Operating cash flow compound annual growth rate: 5-year CAGR of -30.1%, 10-year CAGR of 11.2%, 20-year CAGR of 25.0%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $941.54M
- Implied Share Price
- $13.73
- Enterprise Value
- $3.70B
- Revenue (TTM)
- $2.67B
- EBITDA
- $484.60M
- Profit Margin
- -39.20%
- Trailing P/E
- —
- Forward P/E
- 9.59
- Price/Book (MRQ)
- 0.42
- Price/Sales (TTM)
- 0.35
- EV/EBITDA
- 22.78
- EV/Revenue
- 1.38
- Dividend Yield
- —
- Book Value
- $25.99
- Free Cash Flow (FY2025)
- -$83.00M
- Free Cash Flow Yield
- -8.82%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.